Pharmaceuticals

Landmark Phase 3 trial shows TECVAYLI dramatically improves survival in early relapse, poised to become a new standard of care for multiple myeloma.

The specialty infusion provider taps veteran Dan Teich for a new SVP role, aiming to streamline partner relations and accelerate its growth to 50+ locations.

Cumberland Pharmaceuticals and SciClone launch Vibativ in China, offering a new defense against deadly, drug-resistant bacteria in a high-stakes market.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.

With Ozempic at generic prices and a new free-to-start model, Felix Health is making high-demand weight-loss drugs more accessible than ever for Canadians.

BeOne Medicines' immunotherapy TEVIMBRA gains key reimbursement nods, paving the way for Canada's first funded option for a rare head and neck cancer.

ZYUS secures high-interest debt to stay afloat, but a trading halt and unresolved accounting issues raise serious questions about its long-term resilience.

A new telehealth platform offers popular weight loss drugs for $149/month, but there's a catch: they aren't FDA-approved. Here's what you need to know.

A new compounding base from PCCA blends peptides, exosomes, and zinc hyaluronate, aiming to redefine customized anti-aging solutions for pharmacists.

Uncommon Productions' 'Cracking the Code' earns top honors, celebrating the biotech revolution and the power of scientific ingenuity.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

As a national estrogen patch shortage leaves women scrambling, a 90-day vaginal ring is emerging as a stable alternative in a disrupted HRT market.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

Dutch CDMO Intravacc's new French tax credit approval offers a major financial boost for biotech partners, aiming to accelerate vaccine R&D in Europe.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Wellness brand Le-Vel is launching a telehealth service for prescription peptides, blurring the lines between direct sales and mainstream medicine.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.